Claude Maraoui - 22 Apr 2026 Form 4 Insider Report for Journey Medical Corp (DERM)

Reporting relationship: President & CEO, Director
Issuer ticker: DERM
Reported as of: 22 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Apr 2026, 17:27:06 UTC
Prior SEC filing: 26 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Ramsey Alloush, attorney-in-fact

Filing notes and source

Key filing fact

Claude Maraoui filed Form 4 for Journey Medical Corp (DERM) on 24 Apr 2026.

Key facts

This page summarizes Claude Maraoui's Form 4 filing for Journey Medical Corp (DERM).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 24 Apr 2026, 17:27.

Change

Previous filing in this sequence was filed on 26 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001893880 Primary reporting owner

Maraoui Claude

Relationship: President & CEO, Director
Address: C/O JOURNEY MEDICAL CORPORATION, 9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE
Signature: /s/ Ramsey Alloush, attorney-in-fact
Signature date: 24 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DERM transaction

Common Stock, $0.0001 par value

Award

Transaction value
Shares: +49,277
Change %: +2.1%
Price: $0.000000^*
Shares after: 2,435,990
Date: 22 Apr 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DERM transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +82,915
Change %
Price: $0.000000^*
Shares after: 82,915
Date: 22 Apr 2026
Ownership: Direct
Underlying class: Common Stock, $0.0001 par value
Underlying amount: 82,915
Exercise price: $5.04
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

On April 22, 2026, the reporting person was granted 49,277 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 16,426 shares on April 22, 2027, 16,426 shares on April 22, 2028 and 16,425 shares on April 22, 2029.

Footnote F2

Includes restricted stock units, which vest over various time periods.

Footnote F3

On April 22, 2026, the reporting person was granted 82,915 stock options pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 27,638 shares on April 22, 2027, 27,638 shares on April 22, 2028 and 27,639 shares on April 22, 2029.